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Abstract Nebivolol is a third-generation b-adrenergic receptor antagonist (b-blocker)
with high selectivity for b1-adrenergic receptors. In addition, it causes vasodi-
latation via interaction with the endothelial L-arginine/nitric oxide (NO)
pathway. This dual mechanism of action underlies many of the haemodynamic
properties of nebivolol, which include reductions in heart rate and blood
pressure (BP), and improvements in systolic and diastolic function. With re-
spect to BP lowering, the NO-mediated effects cause a reduction in peripheral
vascular resistance and an increase in stroke volume with preservation of car-
diac output. Flow-mediated dilatation and coronary flow reserve are also in-
creased during nebivolol administration. Other haemodynamic effects include
beneficial effects on pulmonary artery pressure, pulmonary wedge pressure,
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exercise capacity and left ventricular ejection fraction. In addition, nebivolol
does not appear to have adverse effects on lipid metabolism and insulin sen-
sitivity like traditional b-blockers. The documented beneficial haemodynamic
effects of nebivolol are translated into improved clinical outcomes in patients
with hypertension or heart failure. In patients with hypertension, the incidence of
bradycardiawith nebivolol is often lower than that with other currently available
b-blockers. This, along with peripheral vasodilatation and NO-induced benefits
such as antioxidant activity and reversal of endothelial dysfunction, should fa-
cilitate better protection from cardiovascular events. In addition, nebivolol has
shown an improved tolerability profile, particularly with respect to events
commonly associated with b-blockers, such as fatigue and sexual dysfunction.
Data from SENIORS (Study of the Effects of Nebivolol Intervention on Out-
comes and Rehospitalization in Seniors with Heart Failure) showed that sig-
nificantly fewer nebivolol versus placebo recipients experienced the primary
endpoint of all-causemortality or cardiovascular hospitalization. The benefits of
nebivolol therapy were shown to be cost effective. Thus, nebivolol is an effective
and well tolerated agent with benefits over and above those of traditional
b-blockade because of its effects on NO release, which give it unique haemo-
dynamic effects, cardioprotective activity and a good tolerability profile.
b-Adrenergic receptor a tagonists (b-block-
ers) play an important role in the management of
cardiovascular disease, including hypertension,
coronary artery disease and chronic heart failure.
However, the role of traditional b-blockers in the
treatment of hypertension has recently been
questioned,[1,2] leading to these agents no longer
being recommended as first- or second-line ther-
apy for hypertension.[3] Third-generation b-
blockers with b1-adrenergic receptor selectivity,
such as nebivolol, have been used effectively in
patients with hypertension,[4-11] heart failure[12,13]
and left ventricular (LV) dysfunction.[12,13]
This review focuses on the haemodynamic ef-
fects of nebivolol, alongwith other ancillarymech-
anisms of action that differentiate it from
traditional b-blockers and may contribute to bene-
ficial cardiovascular effects. Haemodynamics and
other activity are considered in general initially,
then discussed with respect to the use of nebi-
volol in the treatment of cardiovascular disease.
1. Mechanisms of Action
1.1 Differences Between b-Blockers
b-Blockers vary with respect to several phar-
macological properties, including intrinsic sym-
pathomimetic activity, selectivity for b1- and/or
b2-receptors, and additional properties, including
peripheral vasodilatation.[14-16] Intrinsic sym-
pathomimetic activity is not considered to be a
desirable feature because increased sympathetic
stimulation has adverse effects on the heart. In
contrast, receptor selectivity and peripheral vaso-
dilatation are important properties for a b-blocker.
One of themain differences between b-blockers
is selectivity for b1-adrenergic receptors. b1-
Selective agents include metoprolol, bisoprolol,
atenolol and, with the greatest degree of selec-
tivity, nebivolol. b1-Adrenergic receptors are
most numerous in the heart, and selectivity for
this subtype of b-adrenergic receptor limits ad-
verse effects resulting from blockade of b2-adre-
nergic receptors in the lungs and vascular beds.
Most, if not all, the negative effects of sympa-
thetic stimulation are mediated by b1-adrenergic
receptors,[17,18] whereas stimulation of b2-adre-
nergic receptors may have potentially beneficial
effects. These include inhibition of apoptosis and
LV remodelling as well as other favourable ac-
tions on myocardial cell biology.[14,19,20] How-
ever, selectivity is dose dependent, and decreases
or disappears when higher dosages are used. On
the other hand, the favourable effects of carvedilol,
compared with metoprolol, on LV function[21]
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and outcomes[22] in patients with heart failure are
probably not explained by differences in receptor
selectivity but rather by other characteristics of
this agent such as its peculiar binding character-
istics to the b1- and b2-adrenergic receptors,
and ancillary antioxidant and anti-proliferative
properties.[14,15]
Concomitant peripheral vasodilatation is an
important characteristic of third-generation b-
blockers such as carvedilol and nebivolol. Vaso-
dilatation may be achieved through concomitant
blockade of a1-adrenergic receptors (in the case
of labetalol and carvedilol) or via stimulation
of nitric oxide (NO) release (nebivolol).[23] Vaso-
dilatation may allow greater efficacy in the
treatment of cardiovascular diseases, such as
hypertension, coronary artery disease and heart
failure, through a decrease in peripheral and coro-
nary vascular resistance and a lower LV afterload.
The presence of peripheral vasodilator activity
may also result in better tolerability for patients
with concomitant peripheral vascular disease.
1.2 b1-Adrenergic Receptor Selectivity
Nebivolol is a lipophilic, third-generation b-
blocker consisting of a racemic mixture of d- and
l-nebivolol.[24,25] In contrast to other b-blockers,
nebivolol offers a unique mix of b1-selectivity and
NO-mediated vasodilatation. Firstly, it is a
highly selective b-blocker with high selectivity for
b1-adrenergic receptors. The relative selectivity of
nebivolol for the b1-adrenergic receptor in human
myocardium [expressed as Ki(b2)/Ki(b1)] is 40.7,
which is considerably higher than that of biso-
prolol (15.6), metoprolol (4.23), carvedilol (0.73)
and bucindolol (0.49).[24,26]
1.3 Nitric Oxide Release
The second major mechanism of action of ne-
bivolol is NO-mediated vasodilatation.[17,23,25-28]
This is likely to be mediated by stimulation of b3-
adrenergic receptors.[23,28-31] These receptors have
been traditionally related to metabolic effects of
sympathetic stimulation (lipolysis in adipocytes,
insulin sensitivity). However, more important
actions, because of their greater expression in
these tissues, have been described in the periph-
eral vessels and the heart.[23,28-31] In the periph-
eral vessels, b3-adrenergic receptors are expressed
in the endothelial cells where they stimulate endo-
thelial NO synthase (eNOS) with increased NO
release. NO produced at the endocardial level
may paracrinally promote cardiomyocyte relaxa-
tion and improve left ventricular filling. Other
b3-adrenergic receptors are located in the cardio-
myocytes, where they have negative inotropic ef-
fects mediated by G-a-I coupling with NOS and
NO-mediated inhibition of b1- and b2-adrenergic
effects on cardiac muscle.[31] Thus, b3-adrenergic
receptor stimulation causes NO-mediated peri-
pheral vasodilatation, increased myocardial
compliance (through the paracrine effects of endo-
cardial NO release) and inhibition of the ino-
tropic effects of b1- and b2-adrenergic receptor
stimulation. These mechanisms are likely to be
beneficial as they reduce cardiac load, improve
cardiac filling and protect the myocardium from
the untoward effects of xcessive sympathetic
stimulation.
Experimental studies have consistently shown
that nebivolol-induced NO release is likely to be
mediated by b3-adrenergic receptor stimula-
tion.[31] Nebivolol has been shown to dose-
dependently increase phospholipase A2 activity and
stimulate intracellular cyclic adenosine mono-
phosphate (cAMP) production in endothelial
cells.[31] Stimulation of cAMP was not inhibited
by either propranolol (a b1/b2-adrenergic re-
ceptor antagonist) or butaxamine (a selective
b2-adrenergic receptor antagonist).[31] However,
bupranolol, an antagonist at b1-, b2- and b3-
adrenergic receptors, reduced cAMP in cells treated
with nebivolol, implying a role for b3-adrenergic
receptors in the NO-mediated vasodilatory effect
of nebivolol.[31] Increased NO release after nebi-
volol administration causes peripheral vasodila-
tation, improves endothelial function and has
antioxidant effects.
The b1-selective antagonist and b3-receptor
agonist activity of nebivolol are also associated
with beneficial metabolic effects, including in-
creased insulin sensitivity.[32,33] A thorough dis-
cussion of these effects goes beyond the aims of
this review; however, they further differentiate
nebivolol from traditional b-blockers, which may
Nebivolol 43
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worsen insulin sensitivity and the lipid profile.[34]
For example, one double-blind, parallel-group
study showed a significant decrease in total cho-
lesterol and low-density lipoprotein cholesterol
plasma levels after nebivolol treatment, rather than
the increase expected with traditional b-blockers.[35]
Similarly, controlled studies have shown that
nebivolol, in contrast to conventional b-blockers
such as atenolol or metoprolol, can improve insulin
sensitivity, oxidative stress, plasma adiponectin
and soluble selecti plasma levels in patients with
hypertension and/or diabetes mellitus.[32,33,36,37]
All these metabolic effects of nebivolol, as well as
NO release, appear to bemediated via b3-adrenergic
receptor stimulation.[30] Table I summarizes the
mechanisms thought to underlie the beneficial
effects of nebivolol.
2. Haemodynamic Effects of Nebivolol
2.1 Heart Rate
Similar to other b-blockers, nebivolol reduces
resting and exercise heart rate. Resting heart rate
is decreased to a similar or lesser extent[5] by nebi-
volol than with other b-blockers (e.g. bisopro-
lol, metoprolol and atenolol). In addition, the
decrease in heart rate at peak exercise with nebi-
volol is of lower magnitude than with other
b-blockers.[39-41] Therefore, nebivolol may have
fewer unfavourable effects on exercise capacity
than other b-blockers.[34,39,41,42] Less bradycardia
may also contribute to making nebivolol better
tolerated than other b-blockers and assist with
the maintenance of cardiac output.[43] In a dou-
ble-blind, randomized study comparing the ef-
fects of nebivolol and atenolol in 25 patients with
uncomplicated essential hypertension, stroke vol-
ume increased from 72 – 12 to 87 – 15mL, while
cardiac output was maintained (from 4.8 – 0.7 to
5.2 – 0.5 L/min) in patients receiving nebivolol.[44]
2.2 Peripheral Vasodilatation and
Endothelial Function
Experimental studies have shown that nebi-
volol, in contrast to other b-blockers, may reduce
peripheral vascular resistance and blood pressure
(BP) even after acute administration.[45] At low
doses, the reduction in BP is accompanied by no
change, or a slight increase, in cardiac output
and stroke volume, whereas these variables are
decreased by other b-blockers, such as propra-
nolol and atenolol. When nebivolol is adminis-
tered at higher doses, b-blockade may prevail
with an associated decline in cardiac output and
stroke volume, and a slight increase in LV filling
pressures.[45]
The vasodilatory effects of nebivolol have also
been documented in humans. In a comparative,
randomized, double-blind, crossover study, both
nebivolol 5mg/day and bisoprolol 10mg/day,
administered for 2 weeks, reduced systolic BP
(SBP) and diastolic BP (DBP) to a similar extent,
whereas only nebivolol reduced the systemic vas-
cular resistance index (2854 – 201 to 2646 – 186
dynseccm-5m2; p< 0.05).[43] Peripheral vaso-
dilatation after nebivolol administration is
caused byNO release. It is therefore an indication
of improved endothelial function, an important
prognostic factor in patients with a wide spec-
trum of cardiovascular diseases.[28,46-49]
The role of NO release was first shown by
Cockcroft et al.[50] In this study, blood flow was
measured using venous occlusion plethysmogra-
phy during brachial artery infusion of different
agents. Specifically, the effect of NG-monomethyl
Table I. Overview of the haemodynamic properties of nebivolol
(adapted from Moen and Wagstaff,[38] with permission)
ﬂ Blood pressure
ﬂ Heart rate
› LVEF (improvement of systolic function)
› E/A ratio (improvement of diastolic function)
› Stroke volume
Maintenance of cardiac output
ﬂ LV mass
ﬂ Vascular resistance
Improves endothelial function
ﬂ Large artery stiffness
ﬂ Platelet aggregation
No effect on exercise capacity or oxygen consumption
No effect on glucose or lipid metabolism
E/A = ratio of early to late atrial peak filling velocity; LV = left ventric-
ular; LVEF = left ventricular ejection fraction; ﬂ indicates decrease;
› indicates increase.
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L-arginine (L-NMMA), a competitive inhibitor
of NOS, on forearm blood flow (FBF) was com-
pared with that of carbachol (an endothelium-
dependent agonist) and sodium nitroprusside
(an endothelium-independent vasodilator). It was
found that nebivolol increased FBF by 91 – 18%
(n = 8; p< 0.01) and that this effect was inhibited
by L-NMMA (by 65 – 10%) and carbachol (by
49 – 8%). Inhibition of the response to nebivolol
by L-NMMAwas, in turn, abolished by L-arginine.
These data show that nebivolol dilates peripheral
vascular resistance vessels via the L-arginine/NO
pathway (figure 1).[50]
Later studies confirmed these results. In one
study in 35 patients with stable coronary artery
disease, nebivolol administration for 4 weeks
improved flow-mediated dilation (FMD) com-
pared with baseline (5.6 – 2.9% vs 3.9 – 2.7%;
p= 0.047). In contrast, patients treated with ate-
nolol did not show any increase in FMD.[51] In
another study, 12 hyperte sive patients were
randomized in a double-blind crossover fashion
to 8 weeks’ treatment with either nebivolol
5mg/day or atenolol 50mg/day, both in combi-
nation with bendroflumethiazide 12.5mg/day.[52]
Stimulated and basal endothelium-dependent
NO release were assessed by forearm venous
occlusion plethysmography after intra-arterial
infusions of acetylcholine and L-NMMA, res-
pectively. Sodium nitroprusside was used as
an endothelium-independent control. Nebivolol/
bendroflumethiazide and atenolol/bendroflume-
thiazide both reduced BP to the same extent.
The vasodilatory response to acetylcholine was in-
creased with nebivolol/bendroflumethiazide (maxi-
mum percentage change in FMD 435 – 27%;
p < 0.001) but not with atenolol/bendroflumeth-
iazide (figure 2). Similarly, the endothelium-
dependent vasoconstrictive response to L-NMMA
was significantly improved only with nebivolol
treatment. The response to sodium nitroprusside
was not different between treatments, suggesting
that the endothelium-independent pathway was
unaffected.[52] These data show that the nebivo-
lol/bendrofluazide combination, but not ateno-
lol/bendrofluazide, can increase both stimulated
and basal endothelial NO release and improve
endothelial function in hypertensive patients.
More recently, a study in 40 hypertensive pa-
tients showed that nebivolol, but not atenolol,
improved FMD and decreased plasma levels of
asymmetric dimethylarginine (ADMA), a natu-
rally occurring amino acid that inhibits eNOS,
with a significant correlation between these
changes.[53] Moreover, sera derived from patients
treated with nebivolol, but not atenolol, decreased
ADMA levels and increased dimethylarginine
dimethylaminohydrolase 2 (the enzyme that se-
lectively degrades ADMA) expression and eNOS
activity.[53] These results confirm that nebivolol
can improve endothelial function in hypertensive pa-
tients and suggest increased degradation ofADMA,
an inhibitor of NOS, as a potential mechanism.
All these data consistently show that nebivolol
causes vasodilatation through its effects on endo-
thelial NO release. Endothelial dysfunction is a
systemic defect that affects both central and peri-
pheral arteries and has an impact on the cardio-
vascular event rate.[47] Therefore, it could be
hypothesized that nebivolol may further reduce
cardiovascular risk compared with traditional
b-blockers.
Stimulation of NO release by nebivolol admin-
istration may also be associated with favourable
effects on sexual function. It has been shown that
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Fig. 1. Nebivolol vasodilates human forearm vasculature in healthy
male subjects (n= 40). First evidence of an L-arginine/nitric oxide-
dependent mechanism (reproduced from Cockcroft et al.,[50] with
permission). FBF = forearm blood flow.
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nebivolol, but not metoprolol, can induce eNOS
activation and NO liberation in murine corpus
cavernosum.[54] The reported incidence of erectile
dysfunction and worsening of sexual function in
hypertensive men is lower during treatment with
nebivolol compared with other b-blockers.[55-57]
Hence, compliance with nebivolol therapy may be
greater than with traditional b-blockers in patients
with a variety of cardiovascular diseases.
2.3 Coronary Blood Flow
b-Blockers have multiple effects on coronary
blood flow. Bradycardia decreases myocardial
oxygen consumption and increases the duration
of diastole – the phase of the cardiac cycle during
which coronary blood flow is maximal. Secondly,
b-blockers have direct effects on coronary circu-
lation. Blockade of b1- and b2-adrenergic recep-
tors by nonselective agents may lead to greater
stimulation of a1-adrenergic receptors by nora-
drenaline (norepinephrine), resulting in coronary
vasoconstriction. However, b1-selective agents
such as nebivolol may allow stimulation of vas-
cular b2-adrenergic receptors without associated
vasoconstriction.[58]
The effects of nebivolol administration on
coronary flow reserve (CFR) have been studied.
CFR represents the capacity of the coronary cir-
culation to dilate following an increase in myo-
cardial metabolic demands. CFR is expressed as
the difference between the hyperaemic flow and
resting flow curves, and is assessed clinically using
perfusion imaging and, more recently, trans-
oesophageal or transthoracic Doppler echocar-
diography. Using these techniques, CFR of the
left anterior descending artery can be measured.
Impaired CFR has been noted in patients with
diabetes, hypertension and idiopathic dilated
cardiomyopathy (IDC), in whom it predicts a poor
prognosis.[59] The mechanisms by which arterial
hypertension can bring about changes in CFR are
numerous, and include increased afterload, LV
hypertrophy and endothelial dysfunction.
The potential for nonspecific b-blockers to
improve CFR is limited by their tendency to
cause vasoconstriction through b2-adrenergic
receptor antagonism. On the other hand, the vaso-
dilatory properties of nebivolol should theoreti-
cally preserve CFR. Indeed, clinical studies have
confirmed that nebivolol may improve CFR in
patients with hypertension without coronary
heart disease and in those with IDC. Following
treatment with nebivolol, CFR was increased in
14 subjects with newly diagnosed hypertension
with or without LV hypertrophy.[60] CFR was
measured at baseline and following 4 weeks’
treatment with nebivolol 5mg/day, using low-
dose dipyridamole Doppler echocardiography at
the level of the distal left anterior ascending art-
ery. Nebivolol administration did not change
coronary flow velocity at rest but was associated
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with an increase in coronary diastolic peak velo-
city after dipyridamole (25.8 – 5.1 vs 47.9 – 7.3;
p< 0.03) leading to an improvement in CFR
(2.12 – 0.33 vs 1.89 – 0.31 at baseline; p< 0.0001).
In two-thirds of the patients, the increase in CFR
was ‡8%, which represents a biologically relevant
change in this parameter.
In another comparative trial, the effects of
nebivolol 5mg/day on CFR were compared with
those of atenolol 50mg/day in 63 hypertensive
patients using an 8-week, crossover design.
Compared with baseline, nebivolol induced a
nonsignificant increase in CFR (from 2.45 to
2.56; p= 0.09), while atenolol was associated with
a significant reduction in CFR (from 2.46 to 2.21;
p= 0.006).[61]
Thus, unlike other b-blockers, nebivolol has
beneficial effects on CFR. This activity is likely to
be related to peripheral and coronary NO-medi-
ated vasodilatation, as well as to afterload re-
duction and reduced LV end-diastolic pressure.
These effects may have clinical implications be-
cause patients with hypertension often have re-
duced CFR and exercise-induced subendocardial
ischaemia.
Patients with IDC may also have impaired
coronary blood flow and CFR. LV dilatation and
eccentric hypertrophy, tachycardia, and a re-
duced pressure gradient for coronary blood flow
caused by increased end-diastolic LV pressure
and/or lower aortic pressure, may also favour
subendocardial ischaemia despite normal cor-
onary arteries. Improving CFR is therefore a
potentially important therapeutic target for heart
failure treatment. Administration of nebivolol to
patients with IDC has been shown to significantly
increase coronary velocities after dipyridamole,
resulting in a greater CFR (2.02 – 0.35 vs
2.61 – 0.43; p < 0.001), with an absolute CFR in-
crease of 6% in 17 of 21 patients.[62]
2.4 Left Ventricular (LV) Function
Bradycardia, peripheral vasodilatation and
improved endothelial function are accompanied
by an improvement in systolic and diastolic LV
function after nebivolol administration. This has
been shown consistently by many studies con-
ducted in patients with hypertension or heart
failure.[63,64]
These effects of nebivolol must be assessed in
the context of the effects of b-blocker therapy on
LV function. Many b-blockers, without and with
ancillary properties (e.g. metoprolol, bisoprolol,
carvedilol and bucindolol) have been con-
sistently shown to improve LV systolic function
after long-term administration to patients with
heart failure.[16,17,21] With nebivolol, the bene-
ficial effects of long-term b-adrenergic blockade
may be accompanied by its favourable short- and
long-term effects related to NO release.
Vasodilatation caused by NO release in the
peripheral vessels may counteract the decrease in
myocardial contractility caused by b1-adrenergic
receptor antagonism, so that nebivolol adminis-
tration may be better tolerated in the short-term,
similar to what has been seen with other b-
blockers that have associated vasodilatory prop-
erties.[65] The cardiac release of NO may also
have some effects.
Cardiac NO production may have a profound
impact on cardiac function through both vascular-
dependent and vascular-independent effects.
Vascular-dependent mechanisms include regula-
tion of coronary vessel tone, thrombogenicity,
proliferative and inflammatory properties, and
angiogenesis.[29] Direct effects of NO on myocar-
dial contractility and diastolic function are medi-
ated by changes in the excitation-contraction
coupling, presynaptic and postsynaptic modula-
tion of autonomic signalling, and changes in mito-
chondrial respiration.[66,67] Nebivolol has been
shown to induce NO release in the heart through
inducible NOS activation.[68] Thus, nebivolol
may also affect cardiac function via these mech-
anisms, in addition to b1-adrenergic receptor
antagonism.
The results of the main studies investigating
the effects of nebivolol on LV function in patients
with normal LV function (either healthy subjects
or those with essential hypertension) or LV dys-
function will be detailed separately.
2.4.1 Subjects with Normal LV Function
Investigations in healthy subjects and in pa-
tients with essential hypertension and normal LV
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function have confirmed that nebivolol may re-
duce BP with no change or an improvement in
variables related to LV systolic performance such
as the systolic time intervals, ejection fraction and
stroke volume.
The ratio of the heart rate-corrected pre-
ejection period (PEPc) to the LV ejection time
(LVET) is inversely related to LV systolic perfor-
mance and directly related to peripheral vascular
resistance. In a comparative study in healthy vol-
unteers, the PEPc/LVET ratio increased after
1month of treatment with propranolol or atenolol
(consistent with their negative inotropic activity),
remained unchanged after pindolol (because of
its intrinsic sympathetic activity) and progres-
sively decreased with nebivolol.[69]
Results obtained in patients with arterial
hypertension are consistent with these findings.
Nebivolol decreased SBP and DBP with no
change or a slight increase in cardiac output and
stroke volume, and no significant change in right
ventricular and LV filling pressures.[69,70]
LV diastolic function may also be favourably
influenced by nebivolol administration, via bra-
dycardia, peripheral vasodilatation and afterload
reduction, along with stimulation of cardiac NO
release. Nebivolol has also been shown to sig-
nificantly improve variables related to early LV
filling, such as the early transmitral peak flow
velocity and the LV peak filling rate, both in
healthy volunteers and in patients with essential
hypertension.[39,44,48,69,70]
2.4.2 Patients with Heart Failure and Preserved
LV Systolic Function
One prospective, parallel-group, randomized
study in 30 patients with mild arterial hyperten-
sion and chronic heart failure secondary to LV
diastolic dysfunction, and diagnosed on the basis
of high pulmonary wedge pressure, compared
the effects of long-term administration of atenolol
or nebivolol on exercise capacity, and haemo-
dynamic parameters at rest and during maximal
exercise.[40] Both b-blockers improved clinical symp-
toms of heart failure, and decreased heart rate
and BP. However, only nebivolol significantly
improved exercise capacity, accompanied by a
greater improvement in LV diastolic function
compared with atenolol. Cardiac index declined
to a lesser extent in nebivolol recipients, and
there was a greater increase in stroke volume
index and a greater decline in mean pulmonary
artery pressure and pulmonary wedge pressure,
both at rest and peak exercise. At rest, cardiac
index changed from a mean baseline value of
3.62 – 0.51 to 2.98 – 0.46L/min/m2 at 6 months in
atenolol-treated patients and from 3.46 – 0.45 to
3.20 – 0.48L/min/m2 in nebivolol-treated patients
over the same period (p < 0.01 for intergroup dif-
ference). Systemic vascular resistance at rest, ex-
pressed as dynscm-5, changed from 1405 – 239
to 1523 – 352 in atenolol-treated patients and
from 1366 – 228 to 1334 – 243 in nebivolol recip-
ients (p < 0.05). During exercise, the negligible
effect of nebivolol versus atenolol on cardiac in-
dex was even more apparent than at rest (change
from 5.85 – 1.22 to 5.31 – 1.26 for atenolol vs
5.84 – 1.83 to 5.79 – 1.80 for nebivolol; p = 0.005
between groups). Regression of LV hypertrophy
and the effects of nebivolol on peripheral resis-
tance and LV diastolic function were suggested
by the authors as possible mechanisms to account
for the differences observed between nebivolol
and atenolol. These haemodynamic improve-
ments and the increase in exercise tolerance after
nebivolol could also be ascribed to the ancillary
effects of this b-blocker on NO release, which
may cause both vasodilatation and a greater im-
provement in LV diastolic function.
2.4.3 Patients with LV Systolic Dysfunction:
Short-Term Studies
The acute haemodynamic effects of nebivolol
and atenolol, administered intravenously, have
been compared by left heart catheterization in
patients with mild post-infarction LV dysfunc-
tion.[42] Intravenous nebivolol 2.5mg was asso-
ciated with a reduction in heart rate similar to
that of intravenous atenolol 15mg. However,
nebivolol did not affect the cardiac index, slightly
but significantly increased the stroke volume
index and ejection fraction, and reduced the LV
end-diastolic pressure and the pressure at the
time of mitral valve opening. In contrast, atenolol
reduced cardiac index, stroke volume index
and ejection fraction, and slightly increased LV
48 Kamp et al.
ª 2010 Adis Data Information BV. All rights reserved. Drugs 2010; 70 (1)
This material is
the copyright of the
original publisher.
Unauthorised copying
and distribution
is prohibited.
pressures. These different haemodynamic effects
may be explained by the vasodilatory action of
nebivolol. However, despite a similar reduction
in mean LV wall stress, atenolol decreased the
ejection fraction, consistent with its negative ino-
tropic action, while nebivolol increased ejec-
tion fraction.[42] This difference, despite a similar
afterload reduction, may be attributed to in-
creased cardiac NO release after nebivolol
administration.
Significant differences between nebivolol and
atenolol were also found for effects on LV dia-
stolic function. Nebivolol, but not atenolol, in-
creased the peak filling rate and shifted the LV
pressure-volume curve downward, consistent
with an improvement in LV compliance.[42] These
changes appeared to be the result of peripheral
vasodilatation, with venous dilatation causing a
smaller right ventricular volume and a secondary
improvement in LV filling.[42] Another study
compared the acute haemodynamic effects of
nebivolol and atenolol, administered orally ra-
ther than intravenously, in patients with LV
dysfunction after coronary artery bypass graft-
ing.[71] Nebivolol 5mg and atenolol 50mg in-
duced a similar decline in heart rate and BP.
However, cardiac index and stroke volume index
decreased significantly after atenolol, but re-
mained unchanged 6 hours after nebivolol ad-
ministration and improved significantly after
24 hours. These observations were related to the
different effects of the two agents on systemic
vascular resistance, which increased after ateno-
lol and declined after nebivolol, with significant
changes after 24 hours. The echo-Doppler study
showed an increase in the acceleration of aortic
flow velocity and a decline of the isovolumic re-
laxation time, consistent with an improvement in
diastolic function, with nebivolol but not with
atenolol.[71]
Other studies evaluated the medium term (1–6
weeks) effects and tolerability of nebivolol in
patients with symptomatic, New York Heart
Association (NYHA) class III–IV[72] or II–III[73]
congestive heart failure. When started at a low
dose (1mg/day) with a gradual up-titration to the
final dose of 5mg/day, nebivolol was well toler-
ated even in patients with advanced, class III–IV
disease. In this study, nebivolol significantly
reduced heart rate, while all the other haemo-
dynamic variables remained unchanged.[72] In
another study, haemodynamic measurements
were performed at rest and during bicycle ex-
ercise using right heart catheterization, at base-
line and after 1 week of treatment. Similar to the
other studies, nebivolol was associated with a
decline in heart rate and BP, along with an in-
crease in stroke volume and no significant change
in any other variables.[73]
All these investigations show that nebivolol is
well tolerated even when administered to patients
with advanced heart failure. The lack of im-
provement in haemodynamic variables is likely to
be a result of the relatively short (1–6 weeks)
duration of these studies. In fact, the effects of
b-blockers on LV function are time dependent,
and at least 3 months’ treatment is necessary to
obtain a significant improvement in haemodyna-
mic variables in patients with heart failure.[16,17]
2.4.4 Patients with LV Systolic Dysfunction:
Long-Term Studies
Administration of b-blockers has been shown
to be the most effective treatment for improving
LV function and prognosis in patients with heart
failure. Accordingly, a significant improvement
in LV function has been observed in studies as-
sessing the medium- to long-term effects of nebi-
volol administration.
LV function and exercise tolerance were stu-
died at baseline and after 8–10 weeks in 40 pa-
tients with post-infarction LV dysfunction (mean
ejection fraction 35.6 – 6.1%) but no overt heart
failure, randomized to placebo, nebivolol 2.5
or 5mg/day or atenolol 50mg/day.[41] Both b-
blockers significantly reduced heart rate, al-
though the effect of atenolol was greater than
that of nebivolol. LV pressures during ejection
were also significantly reduced by both agents,
resulting in reduced mean systolic wall stress. LV
ejection fraction significantly improved com-
pared with baseline (+5.3% with atenolol and
+4.3% with nebivolol). Regarding the effects on
LV diastolic function, both dosages of nebivolol,
but not placebo or atenolol, induced a parallel
downward shift of the pressure-volume curve
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with an increase in the peak filling rate and a re-
duction in the time to peak filling rate, compared
with placebo. These variables tended to worsen
after atenolol but these differences were not sig-
nificant. The improvement in the peak filling rate
despite a decrease of the driving pressure after
nebivolol implies an improvement in early diastolic
compliance, which was greater than that observed
by the same investigators with other agents, such
as xamoterol or ACE inhibitors.[41] Lastly, peak
exercise duration remained unchanged in the
placebo- and atenolol-treated patients, while it
improved in those receiving nebivolol (+15.4%
with 2.5mg/day and +15.6% with 5mg/day;
p= 0.0077).[41] This improvement in exercise ca-
pacity seems to be quite a nebivolol-specific effect
because it has not been observed with other vaso-
dilating b-blockers, such as bucindolol or carve-
dilol, in patients with heart failure.[65,74]
Wisenbaugh et al.[75] performed the first con-
trolled study in which follow-up duration was
long enough to detect the effects of b-blockade on
LV function. This study included 24 patients with
idiopathic or ischaemic (n = 2) dilated cardio-
myopathy, in NYHA class II (n = 23) or III (n = 1)
heart failure, with a mean LV ejection fraction of
24%, and who were treated only with furosemide.
Left and right heart catheterization and exer-
cise testing were performed at baseline and after
3 months of therapy with either placebo or nebi-
volol 1–5mg/day. In contrast to the findings of
Rousseau et al.,[41] exercise tolerance was not al-
tered by nebivolol administration. A significant
haemodynamic improvement was detected after
3 months of nebivolol therapy, compared with
placebo. Nebivolol induced a significant decline
in heart rate with a concomitant increase in LV
stroke volume (43 – 9 to 55– 14mL; p = 0.003)
and LV ejection fraction (23 – 8 to 33 – 12%;
p= 0.002), and a slight but significant reduction
in mean pulmonary artery pressure (34 – 11 to
28 – 9mmHg; p = 0.05), LV end-diastolic pressure
(21 – 11 to 15 – 9mmHg; p = 0.03) and LV mass
(228 – 64 to 199 – 52 g/m2; p= 0.04). The relation-
ship between the preload-corrected ejection frac-
tion and end-systolic stress was improved by
nebivolol administration, consistent with an im-
provement in myocardial contractility.[75]
These findings differ from those in short-term
haemodynamic studies, with an improvement in
myocardial contractility and no change in LV
afterload after long-term nebivolol administra-
tion. It is likely that this difference may be ex-
plained by the follow-up duration. Similar to
what is observed with other b-blockers with as-
sociated vasodilatory activity,[65] it is likely that
peripheral vasodilatation is most important in
the short-term when it may counteract the nega-
tive inotropic effect of b-blockade and contribute
to better drug tolerability. However, after long-
term treatment, the improvement in myocardial
function associated with chronic b-blockade may
become more important.
The findings by Wisenbaugh et al.[75] were
confirmed by further studies.[12,63,76] Ghio et al.[63]
reported the results of an echocardiographic sub-
study of the SENIORS (Study of the Effects of
Nebivolol Intervention on Outcomes and Hos-
pitalisation in Seniors with Heart Failure) trial,
designed to evaluate the effects of nebivolol on
systolic and diastolic LV function. The substudy
included 104 patients, 43 with a LV ejection
fraction £35% and 61 with a LV ejection fraction
>35%, assessed before and after 12 months of
treatment. In the patients with a LV ejection
fraction £35%, nebivolol reduced end-systolic
volume by 25.8mL (p = 0.016) and improved LV
ejection fraction by 4.6% (p = 0.008); no changes
were observed in the ratio of early to late atrial
peak filling velocity (E/A ratio) or E-wave decel-
eration time. In the group with LV ejection frac-
tion >35%, no significant changes in either systolic
or diastolic parameters were observed.[12]
3. Clinical Effects
3.1 Hypertension
As stated in the recent guidelines from the
European Society of Hypertension and the Euro-
pean Society of Cardiology (ESC),[77] b-blockers
may still be considered an option for initial and
subsequent antihypertensive treatment strategies.
However, because they have a tendency to increase
bodyweight, have adverse effects on lipid meta-
bolism and increase (compared with other drugs)
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the incidence of new-onset diabetes, b-blockers
are not the agents of choice for treating hyper-
tension in patients with multiple metabolic risk
factors. However, such a recommendation may
not apply to b-blockers such as carvedilol and
nebivolol,[3] which have little or no adverse me-
tabolic effects and are associated with a lower
incidence of new-onset diabetes than traditional
b-blockers.[36,37,77,78] According to the US Joint
National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pres-
sure,[79] b-blockers are the agents of choice when
a patient has concomitant diseases for which
b-blockers have been shown to improve out-
comes (i.e. heart failure, post-myocardial infarc-
tion, coronary artery disease).
As mentioned previously, stimulation of NO
release by nebivolol may be associated with
ancillary effects in patients with hypertension
compared with other b-blockers. These include
antioxidant and anti-inflammatory activity,[32]
reversal of endothelial dysfunction,[52] improve-
ment in coronary blood flow[60] and improve-
ment in LV diastolic function during exercise.[40]
Less bradycardia and peripheral vasodilata-
tion with nebivolol may also have other beneficial
effects. When bradycardia occurs with traditional
b-blockers, the reflected wave reaches the next
wave in systole (instead of diastole), and there-
fore may increase central aortic pressure through
dys-synchrony and uncoupling between the out-
going and reflected waves. This mechanism has
been used to explain the somewhat paradoxical
increase in mortality and cardiovascular event
rate with lower heart rate after treatment with
traditional b-blockers in hypertensive patients.[80]
For example, in the CAFE (Conduit Artery Func-
tional Endpoint) study, central aortic SBP (mea-
sured indirectly by radial artery applanation
tonometry) was higher by 4.3mmHg with atenolol
than with amlodipine for the same peripheral BP.
This was associated with a 14% higher risk of
coronary events and a 23% higher rate of strokes
in atenolol recipients compared with amlodipine,
despite a similar reduction in peripheral BP.[81]
Nebivolol, through itsNO release and peripheral
vasodilatory action, decreases pulse wave velocity,
a measure of arterial stiffness.[82] In a compara-
tive trial, treatment with nebivolol was associated
with a lower central aortic pulse pressure compared
with atenolol (50 – 2 vs 54 – 2mmHg; p= 0.02)
despite similar values for peripheral BP.[83] It
could therefore be hypothesized that the lower
incidence of bradycardia, along with peripheral
vasodilatation and NO release, associated with
nebivolol administration facilitates better protec-
tion from cardiovascular events in hypertensive
patients compared with traditional b-blockers.
Antihypertensive therapy not only needs to be
effective, but also well tolerated. One major
drawback of the currently available b-blockers,
particularly the noncardioselective agents, is their
adverse effect profile, including sexual dysfunc-
tion, fatigue, depression and metabolic abnorm-
alities, such as impaired glucose tolerance and
lipid abnormalities. Nebivolol has a favourable
adverse effect profile, most notably for events
commonly associated with b-blockers, such as
fatigue and sexual dysfunction.[55,56,84] Overall,
the antihypertensive efficacy of nebivolol appears
to be similar to that of other b-blockers, as well as
calcium channel antagonists and renin-angiotensin
antagonists, but with a better adverse effect pro-
file compared with traditional b-blockers.[8,11]
In a multicentre, nationwide observational
study including 6356 patients with mild hyper-
tension, the rate of significant adverse effects
during 6 weeks’ treatment with nebivolol was
only 0.5% and there were no serious adverse ef-
fects.[85] One of the largest double-blind, multi-
centre, randomized, placebo-controlled studies
of nebivolol in hypertension was conducted by
Weiss et al.[86] in 909 patients with mild to
moderate disease. Nebivolol reduced trough
sitting DBP by 8.0–11.2mmHg, compared with
2.9mmHg for placebo (p < 0.001), and trough
sitting SBP by 4.4–9.5mmHg compared with a
2.2mmHg increase in placebo recipients (p= 0.002).
The overall incidence of adverse events was
similar in the nebivolol (46.1%) and placebo
(40.7%) groups (p = 0.273). In particular, the in-
cidence of typical b-blocker-induced adverse
events was not different from placebo, including
erectile dysfunction (0.2% nebivolol vs 0.0% pla-
cebo), decreased libido (0.1% vs 0.0%), dyspnoea
(1.0% vs 0.0%) and bradycardia (0.7% vs 0.0%).[86]
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3.2 Heart Failure
The clinical efficacy and effects of nebivolol on
outcomes in patients with chronic heart failure
has been thoroughly assessed in the SENIORS
trial.[13] Based on the results of this trial, nebivo-
lol is now indicated for the treatment of patients
with heart failure in ESC guidelines.[87] In the
study, a total of 2128 elderly patients (age ‡70 years)
with a clinical history of congestive heart failure
(hospital admission within 12 months or LV
ejection fraction £35%) were randomized to ne-
bivolol or placebo; mean duration of treatment
was 21 months. This trial was one of the first to
include not only patients with a low LV ejection
fraction but also those with preserved systolic
function (LV ejection fraction >35%). The pri-
mary composite endpoint was all-cause mortality
or cardiovascular hospitalization, and secondary
endpoints included cardiovascular mortality,
cardiovascular hospitalization, and the compo-
site of cardiovascular and all-cause mortality and
hospitalization.
Mortality or cardiovascular hospitalization,
the primary endpoint, occurred in fewer patients
receiving nebivolol comparedwith placebo (hazard
ratio [HR] 0.86; 95%CI 0.74, 0.99; p = 0.039). The
cardiovascular mortality or hospitalization rate
was also lower in the nebivolol group than the
placebo group (HR 0.84; 95% CI 0.72, 0.98;
p= 0.027). Prespecified subgroup analyses did not
show any significant interaction between sex,
ejection fraction, age, diabetes or prior myo-
cardial infarction, and the effects of nebivolol on
outcomes. However, the HR for the primary
endpoint was 0.79 (95% CI 0.63, 0.98) in patients
aged less than the median of 75.2 years and 0.92
(95% CI 0.75, 1.12) in those aged >75.2 years
(for interaction test p = 0.51).[13]
In order to assess the effects of nebivolol
therapy in patients comparable to those assessed
in previous b-blocker trials, the authors assessed
the effects of treatment in patients aged less than
the median of 75.2 years and with a LV ejection
fraction £35% (n = 342 for nebivolol and n= 342
for placebo). In this subgroup, the HR for the
primary outcome was 0.73 (95% CI 0.56, 0.96)
and for all-cause mortality alone the HRwas 0.62
(95% CI 0.43, 0.89), which is higher than in the
overall study group and comparable to values
reported in previous b-blocker trials.[13,16,17,87]
Additional analyses also confirmed that the re-
sults were consistent with those from other
b-blocker trials. There was a significant correla-
tion between achievement of nebivolol target
dose (10mg/day) and a more favourable effect of
nebivolol on outcomes (HR 0.73; 95% CI 0.61,
0.87; p < 0.001),[88] and nebivolol treatment was
also shown to be cost effective.[89]
SENIORS is the only trial with data regarding
the effects of nebivolol on outcomes. A detailed
discussion of the significance of its results goes
beyond the scope of this article. However, even in
this context, some issues should be highlighted.
SENIORS was one of the first trials in patients
with chronic heart failure that tried to broaden
the indications for medical therapy and to assess
the effects of treatment in patients with char-
acteristics more similar to real life clinical prac-
tice.[89,90] Thus, elderly patients were included
and inclusion was not based on LV ejection
fraction criteria. These criteria did not show sig-
nificant interaction with the effects of treatment
in subgroup analyses (figure 3).[13] However, re-
sults may have been more significant had the
study included only patients with characteristics
similar to those of previous b-blockers trials.
1.00.80.60.40.20 1.2
Relative risk
COPERNICUS
CIBIS II
MERIT-HF
>65 y
Patient age
>69 y
>71 y
SENIORS70−75 y
All⎧⎨⎩<35%
Fig. 3. Effect of b-blockers on all-cause mortality or cardiovascular
hospitalization in elderly patients; post hoc subgroup analysis from
the SENIORS (Study of the Effects of Nebivolol Intervention on
Outcomes and Hospitalisation in Seniors with Heart Failure) trial in
patients with left ventricular ejection fraction <35%. CIBIS II=Cardiac
Insufficiency Bisoprolol Study II; COPERNICUS=Carvedilol Pro-
spective Randomized Cumulative Survival; MERIT-HF =Metoprolol
CR/XL Randomized Intervention Trial in Heart Failure.
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Thus, as well as showing the beneficial effects of
medical treatment in a wider spectrum of patients
with heart failure, SENIORS was one of the first
trials to show the limitations of large trials in
providing evidence for treatment in elderly pa-
tients with heart failure and those with preserved
LV ejection fraction. Such issues have un-
fortunately been replicated by subsequent trials
with a similar design, although addressing differ-
ent treatments.[90]
4. Conclusion
Nebivolol is a third-generation b-blocker with
a unique haemodynamic profile, combining highly
selective b1-adrenergic receptor antagonism with
NO-mediated vasodilatory activity. The actions
of nebivolol over and above b-blockademay have
important implications with respect to reversal of
endothelial dysfunction, improvement in periph-
eral and coronary blood flow, and antioxidant
and anti-inflammatory activity. These pharma-
cological properties appear to be associated with
better tolerability compared with traditional
b-blockers and may result in additional protec-
tion from cardiovascular events.
Acknowledgements
Editorial assistance with English and preparation for
submission was provided by Nicola Ryan of Wolters Kluwer
with support from A Menarini Farmaceutica Internazionale
srl, Florence, Italy. Professor Metra has received honoraria
for preparation for advisory boards and meetings organized
by companies involved in cardiovascular research, including
Corthera, Merck, Cardiokime and Ostuka. The other authors
have no conflicts of intere t that are directly relevant to the
content of this article.
References
1. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in
hypertension: is it a wise choice? Lancet 2004; 364 (9446):
1684-9
2. Lindholm LH, Carlberg B, Samuelsson O. Should beta
blockers remain first choice in the treatment of primary
hypertension? A meta-analysis. Lancet 2005; 366 (9496):
1545-53
3. National Institute for Health and Clinical Excellence (NICE).
Our guidance [online]. Available from URL: http://www.
nice.org.uk/CG034guidance [Accessed 2009 Nov 23]
4. Czuriga I, Riecansky I, Bodnar J, et al. Comparison of the
new cardioselective beta-blocker nebivolol with bisoprolol
in hypertension: the Nebivolol, BisoprololMulticenter Study
(NEBIS). Cardiovasc Drugs Ther 2003; 17 (3): 257-63
5. Grassi G, Trevano FQ, Facchini A, et al. Efficacy and toler-
ability profile of nebivolol vs atenolol in mild-to-moderate
essential hypertension: results of a double-blind rando-
mized multicentre trial. Blood Press Suppl 2003; 2: 35-40
6. Mazza A, Gil-Extremera B, Maldonato A, et al. Nebivolol
vs amlodipine as first-line treatment of essential arterial
hypertension in the elderly. Blood Press 2002; 11 (3): 182-8
7. Rosei EA, Rizzoni D, Comini S, et al. Evaluation of the
efficacy and tolerability of nebivolol versus lisinopril in the
treatment of essential arterial hypertension: a randomized,
multicentre, double-blind study. Blood Press Suppl 2003; 1:
30-5
8. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and
antihypertensive effect with nebivolol and losartan. Am J
Hypertens 2005; 18 (8): 1060-6
9. Van Nueten L, Lacourciere Y, Vyssoulis G, et al. Nebivolol
versus nifedipine in the treatment of essential hypertension:
a double-blind, randomized, comparative trial. Am J Ther
1998; 5 (4): 237-43
10. Van Nueten L, Schelling A, Vertommen C, et al. Nebivolol
vs enalapril in the treatment of essential hypertension:
a double-blind randomised trial. J HumHypertens 1997; 11
(12): 813-9
11. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs
atenolol and placebo in essential hypertension: a double-
blind randomised trial. J Hum Hypertens 1998; 12 (2):
135-40
12. Edes I, Gasior Z, Wita K. Effects of nebivolol on left ven-
tricular function in elderly patients with chronic heart
failure: results of the ENECA study. Eur J Heart Fail 2005;
7 (4): 631-9
13. Flather MD, Shibata MC, Coats AJ, et al. Randomized
trial to determine the effect of nebivolol on mortality
and cardiovascular hospital admission in elderly patients
with heart failure (SENIORS). Eur Heart J 2005; 26 (3):
215-25
14. Metra M, Cas LD, di Lenarda A, et al. Beta-blockers in
heart failure: are pharmacological differences clinically
important? Heart Fail Rev 2004; 9 (2): 123-30
15. Metra M, Dei Cas L, Cleland JG. Pharmacokinetic and
pharmacodynamic characteristics of beta-blockers: when
differences may matter. J Card Fail 2006; 12 (3): 177-81
16. Metra M, Nodari S, D’Aloia A, et al. A rationale for the use
of beta-blockers as standard treatment for heart failure.
Am Heart J 2000; 139 (3): 511-21
17. Bristow MR. Beta-adrenergic receptor blockade in chronic
heart failure. Circulation 2000; 101 (5): 558-69
18. El-Armouche A, Eschenhagen T. Beta-adrenergic stimula-
tion and myocardial function in the failing heart. Heart
Fail Rev 2009; 14 (4): 225-41
19. Ahmet I, Krawczyk M, Zhu W, et al. Cardioprotective and
survival benefits of long-term combined therapy with beta2
adrenoreceptor (AR) agonist and beta1 AR blocker in di-
lated cardiomyopathy postmyocardial infarction. J Phar-
macol Exp Ther 2008; 325 (2): 491-9
20. Communal C, Singh K, Sawyer DB, et al. Opposing effects
of beta(1)- and beta(2)-adrenergic receptors on cardiac
Nebivolol 53
ª 2010 Adis Data Information BV. All rights reserved. Drugs 2010; 70 (1)
This material is
the copyright of the
original publisher.
Unauthorised copying
and distribution
is prohibited.
myocyte apoptosis: role of a pertussis toxin-sensitive G
protein. Circulation 1999; 100 (22): 2210-2
21. Metra M, Giubbini R, Nodari S, et al. Differential effects of
beta-blockers in patients with heart failure: a prospective,
randomized, double-blind comparison of the long-term
effects of metoprolol versus carvedilol. Circulation 2000;
102 (5): 546-51
22. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Compar-
ison of carvedilol and metoprolol on clinical outcomes in
patients with chronic heart failure in the Carvedilol Or
Metoprolol European Trial (COMET): randomised con-
trolled trial. Lancet 2003; 362 (9377): 7-13
23. Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol.
Ther Adv Cardiovasc Dis 2009; 3: 317-27
24. Bristow MR, Nelson P, Minobe W, et al. Characterization
of b1-adrenergic receptor selectivity of nebivolol and various
other beta-blockers in human myocardium [abstract no.
P-121]. Am J Hypertens 2005; 18: 51-2A
25. Brixius K, Bundkirchen A, Bolck B, et al. Nebivolol, bu-
cindolol, metoprolol and carvedilol are devoid of intrinsic
sympathomimetic activity in human myocardium. Br J
Pharmacol 2001; 133 (8): 1330-8
26. Ignarro LJ. Different pharmacological properties of two
enantiomers in a unique beta-blocker, nebivolol. Cardio-
vasc Ther 2008; 26 (2): 115-34
27. Gupta S, Wright HM. Neb volol: a highly selective beta1-
adrenergic receptor blocker that causes vasodilation by
increasing nitric oxide. Cardiovasc Ther 2008; 26 (3): 189-202
28. Kuroedov A, Cosentino F, Luscher TF. Pharmacological
mechanisms of clinically favorable properties of a selective
beta1-adrenoceptor antagonist, nebivolol. Cardiovasc
Drug Rev 2004; 22 (3): 155-68
29. Rozec B, Erfanian M, Laurent K, et al. Nebivolol, a vaso-
dilating selective beta(1)-blocker, is a beta(3)-adrenoceptor
agonist in the nonfailing transplanted human heart. J Am
Coll Cardiol 2009; 53 (17): 1532-8
30. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adre-
noreceptors mediate nitric oxide-dependent vasorelaxation
of coronary microvessels in response to the third-genera-
tion beta-blocker nebivolol. Circulation 2005; 112 (8):
1198-205
31. Balligand JL. Beta(3)-adrenoceptor stimulation on top of
beta(1)-adrenoceptor blockade ‘‘stop or encore?’’. J Am
Coll Cardiol 2009 Apr 28; 53 (17): 1539-42
32. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects
of nebivolol and metoprolol on oxidative stress, insulin
resistance, plasma adiponectin and soluble P-selectin levels
in hypertensive patients. J Hypertens 2006; 24 (3): 591-6
33. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol,
a beta-adrenoceptor antagonist with unique character-
istics. Drugs 2007; 67 (8): 1097-107
34. Zanchetti A. Clinical pharmacodynamics of nebivolol: new
evidence of nitric oxide-mediated vasodilating activity and
peculiar haemodynamic properties in hypertensive pa-
tients. Blood Press Suppl 2004; 1: 17-32
35. Lacourciere Y, Poirier L, Lefebvre J, et al. Comparative ef-
fects of a new cardioselective beta-blocker nebivolol and
nifedipine sustained-release on 24-hour ambulatory blood
pressure and plasma lipoproteins. J Clin Pharmacol 1992;
32 (7): 660-6
36. Fogari R, Zoppi A, Lazzari P, et al. Comparative effects
of nebivolol and atenolol on blood pressure and insulin
sensitivity in hypertensive subjects with type II diabetes.
J Hum Hypertens 1997; 11 (11): 753-7
37. Poirier L, Cleroux J, Nadeau A, et al. Effects of nebivolol
and atenolol on insulin sensitivity and haemodynamics in
hypertensive patients. J Hypertens 2001; 19 (8): 1429-35
38. MoenMD,Wagstaff AJ. Nebivolol: a review of its use in the
management of hypertension and chronic heart failure.
Drugs 2006; 66 (10): 1389-409; discussion 410
39. De Cree J, Cobo C, Geukens H, et al. Comparison of the
subacute hemodynamic effects of atenolol, propranolol,
pindolol, and nebivolol. Angiology 1990; 41 (2): 95-105
40. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of
patients with diastolic heart failure and arterial hyperten-
sion: a prospective, randomized, comparison of the long-
term effects of atenolol vs nebivolol. Eur J Heart Fail 2003;
5 (5): 621-7
41. Rousseau MF, Chapelle F, Van Eyll C, et al. Medium-term
effects of beta-blockade on left ventricular mechanics: a
double-blind, placebo-controlled comparison of nebivolol
and atenolol in patients with ischemic left ventricular dys-
function. J Card Fail 1996; 2 (1): 15-23
42. Stoleru L, Wijns W, van Eyll C, et al. Effects of D-nebivolol
and L-nebivolol on left ventricular systolic and diastolic
function: comparison with D-L-nebivolol and atenolol.
J Cardiovasc Pharmacol 1993; 22 (2): 183-90
43. Brett SE, Forte P, Chowienczyk Pj, et al. Comparison of the
effects of nebivolol and bisoprolol on systemic vascular
resistance in patients with essential hypertension. Clin
Drug Invest 2002; 22 (6): 355-9
44. Kamp O, Sieswerda GT, Visser CA. Comparison of effects
on systolic and diastolic left ventricular function of nebi-
volol versus atenolol in patients with uncomplicated
essential hypertension. Am J Cardiol 2003; 92 (3): 344-8
45. Van de Water A, Janssens W, Van Neuten J, et al.
Pharmacological and hemodynamic profile of nebivolol,
a chemically novel, potent, and selective beta 1-adrenergic
antagonist. J Cardiovasc Pharmacol 1988; 11 (5): 552-63
46. Corrado E, Camarda P, Coppola G, et al. Prognostic role of
endothelial dysfunction and carotid intima-media thick-
ness in patients undergoing coronary stent implantation.
Int Angiol 2009; 28 (1): 12-9
47. Landmesser U, Hornig B, Drexler H. Endothelial function:
a critical determinant in atherosclerosis? Circulation 2004;
109 (21 Suppl. 1): II27-33
48. Rossi R, Nuzzo A, Origliani G, et al. Prognostic role of
flow-mediated dilation and cardiac risk factors in post-
menopausal women. J Am Coll Cardiol 2008; 51 (10):
997-1002
49. Sciacqua A, Scozzafava A, Pujia A, et al. Interaction be-
tween vascular dysfunction and cardiac mass increases the
risk of cardiovascular outcomes in essential hypertension.
Eur Heart J 2005; 26 (9): 921-7
50. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol
vasodilates human forearm vasculature: evidence for an
L-arginine/NO-dependent mechanism. J Pharmacol Exp
Ther 1995; 274 (3): 1067-71
51. Lekakis JP, Protogerou A, Papamichael C, et al. Effect of
nebivolol and atenolol on brachial artery flow-mediated
54 Kamp et al.
ª 2010 Adis Data Information BV. All rights reserved. Drugs 2010; 70 (1)
This material is
the copyright of the
original publisher.
Unauthorised copying
and distribution
is prohibited.
vasodilation in patients with coronary artery disease. Car-
diovasc Drugs Ther 2005; 19 (4): 277-81
52. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses
endothelial dysfunction in essential hypertension: a ran-
domized, double-blind, crossover study. Circulation 2001;
104 (5): 511-4
53. Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment
reduces serum levels of asymmetric dimethylarginine and
improves endothelial dysfunction in essential hypertensive
patients. Am J Hypertens 2008; 21 (11): 1251-7
54. Reidenbach C, Schwinger RH, Steinritz D, et al. Nebivolol
induces eNOS activation and NO-liberation in murine
corpus cavernosum. Life Sci 2007; 80 (26): 2421-7
55. Boydak B, Nalbantgil S, Fici F, et al. A randomised com-
parison of the effects of nebivolol and atenolol with and
without chlorthalidone on the sexual function of hyperten-
sive men. Clin Drug Investig 2005; 25 (6): 409-16
56. Brixius K, Middeke M, Lichtenthal A, et al. Nitric oxide,
erectile dysfunction and beta-blocker treatment (MR
NOED study): benefit of nebivolol versus metoprolol in
hypertensive men. Clin Exp Pharmacol Physiol 2007;
34 (4): 327-31
57. Doumas M, Tsakiris A, Douma S, et al. Beneficial effects of
switching from beta-blockers to nebivolol on the erectile
function of hypertensive patients. Asian J Androl 2006;
8 (2): 177-82
58. Galderisi M, D’Errico A. Beta-blockers and coronary flow
reserve: the importance of a vasodilatory action. Drugs
2008; 68 (5): 579-90
59. Rigo F, Gherardi S, Galderisi M, et al. The prognostic im-
pact of coronary flow-reserve assessed by Doppler echo-
cardiography in non-ischaemic dilated cardiomyopathy.
Eur Heart J 2006; 27 (11): 1319-23
60. Galderisi M, Cicala S, D’Errico A, et al. Nebivolol im-
proves coronary flow reserve in hypertensive patients
without coronary heart disease. J Hypertens 2004; 22 (11):
2201-8
61. Gullu H, Erdogan D, Caliskan M, et al. Different effects of
atenolol and nebivolol on coronary flow reserve. Heart
2006; 92 (11): 1690-1
62. Erdogan D, Gullu H, Caliskan M, et al. Nebivolol improves
coronary flow reserve in patients with idiopathic dilated
cardiomyopathy. Heart 2007; 93 (3): 319-24
63. Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in
elderly heart failure patients with or without systolic left
ventricular dysfunction: results of the SENIORS echo-
cardiographic substudy. Eur Heart J 2006; 27 (5): 562-8
64. Lombardo RM, Reina C, Abrignani MG, et al. Effects of
nebivolol versus carvedilol on left ventricular function in
patients with chronic heart failure and reduced left ven-
tricular systolic function. Am J Cardiovasc Drugs 2006;
6 (4): 259-63
65. Metra M, Nardi M, Giubbini R, et al. Effects of short- and
long-term carvedilol administration on rest and exercise
hemodynamic variables, exercise capacity and clinical
conditions in patients with idiopathic dilated cardiomyo-
pathy. J Am Coll Cardiol 1994; 24 (7): 1678-87
66. Casadei B, Sears CE. Nitric-oxide-mediated regulation of
cardiac contractility and stretch responses. Prog Biophys
Mol Biol 2003; 82 (1-3): 67-80
67. Massion PB, Feron O, Dessy C, et al. Nitric oxide and car-
diac function: ten years after, and continuing. Circ Res
2003; 93 (5): 388-98
68. Maffei A, Di Pardo A, Carangi R, et al. Nebivolol in-
duces nitric oxide release in the heart through inducible
nitric oxide synthase activation. Hypertension 2007; 50 (4):
652-6
69. De Cree J, Franken P, Vandevivere J, et al. Hemodynamic
effects of nebivolol in men: comparison of radionuclide
angiocardiography with systolic time intervals. Angiology
1988; 39 (6): 526-34
70. Sanchez RA, Cianciulli T, Dopico AM, et al. Effects of nebi-
volol on LV function in patients with essential hyperten-
sion. Drug Invest 1991; 3 Suppl. 1: 155-60
71. GoldsteinM, Vincent JL, De Smet JM, et al. Administration
of nebivolol after coronary artery bypass in patients with
altered left ventricular function. J Cardiovasc Pharmacol
1993; 22 (2): 253-8
72. Lechat P, Boutelant S, Komajda M, et al. Pilot study of
cardiovascular effects of nebivolol in congestive heart fail-
ure. Drug Invest 1991; 3 Suppl. 1: 69-81
73. Brune S, Schmidt T, Tebbe U, et al. Hemodynamic effects of
nebivolol at rest and on exertion in patients with heart
failure. Angiology 1990; 41 (9 Pt 1): 696-701
74. Metra M, Nodari S, D’Aloia A, et al. Effects of neuro-
hormonal antagonism on symptoms and quality-of-life in
heart failure. Eur Heart J 1998; 19 Suppl. B: B25-35
75. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month)
effects of a new beta-blocker (nebivolol) on cardiac per-
formance in dilated cardiomyopathy. J Am Coll Cardiol
1993; 21 (5): 1094-100
76. Brehm BR, Wolf SC, Gorner S, et al. Effect of nebivolol
on left ventricular function in patients with chronic
heart failure: a pilot study. Eur J Heart Fail 2002; 4 (6):
757-63
77. Mancia G, De Backer G, Dominiczak A, et al. 2007
Guidelines for the management of arterial hypertension:
the Task Force for the Management of Arterial Hyper-
tension of the European Society of Hypertension (ESH)
and of the European Society of Cardiology (ESC). Eur
Heart J 2007; 28 (12): 1462-536
78. Kaiser T, Heise T, Nosek L, et al. Influence of nebivolol and
enalapril on metabolic parameters and arterial stiffness in
hypertensive type 2 diabetic patients. J Hypertens 2006; 24
(7): 1397-403
79. Chobanian AV, Bakris GL, Black HR, et al. The seventh
report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood
Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-72
80. Bangalore S, Sawhney S, Messerli FH. Relation of beta-
blocker-induced heart rate lowering and cardioprotection
in hypertension. J Am Coll Cardiol 2008; 52 (18): 1482-9
81. Williams B, Lacy PS, Thom SM, et al. Differential impact of
blood pressure-lowering drugs on central aortic pressure
and clinical outcomes: principal results of the Conduit
Artery Function Evaluation (CAFE) study. Circulation
2006; 113: 1213-25
82. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol in-
creases arterial distensibility in vivo. Hypertension 2004;
44 (3): 305-10
Nebivolol 55
ª 2010 Adis Data Information BV. All rights reserved. Drugs 2010; 70 (1)
This material is
the copyright of the
original publisher.
Unauthorised copying
and distribution
is prohibited.
83. Dhakam Z, Yasmin, McEniery CM, et al. A comparison
of atenolol and nebivolol in isolated systolic hypertension.
J Hypertens 2008; 26 (2): 351-6
84. Weber MA. The role of the new beta-blockers in treating
cardiovascular disease. Am J Hypertens 2005; 18 (12 Pt 2):
169S-76S
85. Cleophas TJ, Agrawal R, Lichtenthal A, et al. Nationwide
efficacy-safety study of nebivolol in mildly hypertensive
patients. Am J Ther 2006; 13 (3): 192-7
86. Weiss RJ, Weber MA, Carr AA, et al. A randomized,
double-blind, placebo-controlled parallel-group study to
assess the efficacy and safety of nebivolol, a novel beta-
blocker, in patients with mild to moderate hypertension.
J Clin Hypertens (Greenwich) 2007; 9 (9): 667-76
87. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC
guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008: the Task Force for the Diag-
nosis and Treatment of Acute and Chronic Heart Failure
2008 of the European Society of Cardiology. Developed in
collaboration with the Heart Failure Association of the
ESC (HFA) and endorsed by the European Society of In-
tensive Care Medicine (ESICM). Eur Heart J 2008; 29 (19):
2388-442
88. Dobre D, van VeldhuisenDJ,Mordenti G, et al. Tolerability
and dose-related effects of nebivolol in elderly patients with
heart failure: data from the Study of the Effects of Nebi-
volol Intervention on Outcomes and Rehospitalisation in
Seniors with Heart Failure (SENIORS) trial. Am Heart J
2007; 154 (1): 109-15
89. Massie BM. Clinical trials in heart failure: can we expect the
results to be replicated in clinical practice? J Card Fail
1998; 4 (3): 243-7
90. Metra M, Dei Cas L, Massie BM. Treatment of heart failure
in the elderly: never say it’s too late. Eur Heart J 2009;
30 (4): 391-3
Correspondence: Professor Marco Metra, Section of Cardio-
vascular Disease, Department of Experimental and Applied
Sciences, University of Brescia, c/o Spedali Civili; Piazza
Spedali Civili, 25123 Brescia, Italy.
56 Kamp et al.
ª 2010 Adis Data Information BV. All rights reserved. Drugs 2010; 70 (1)
